It is frightening, depressing, etc. and one heck o

It is frightening, depressing, etc. and one heck of a market opportunity. From a marketing perspective one of the keys is the fact of recurrence or lag in manifestation of symptoms or transmission from asymptomatic people who can spread. This means that we are talking about a continual testing/retesting process and that multiplies market demand exponentially over time. Particularly when you consider that no one is guaranteeing that a vaccine would be anything close to completely effective--just as we experience with the various mutating flu strains.

Huge market potential and the fact that the NNLX technology provides initial POC responses rapidly and on-site where the samples don't have to be sent off to labs for final assessment--and that the fact that the NNLX tech is/will be far less expensive than alternatives dependent on labs and PCR is very promising. One problem, of course, is that Pharma and labs want expensive testing and see their profits greatly reduced or eliminated by something potentially 50 to 100 times less costly than their processes and with ease of use and considerably higher accuracy rates.

Be patient. We will be dealing with this for a while. And then we will deal with the next epidemic, etc.